文献速递眼底病与葡萄膜炎

玻璃体腔注射0.19毫克醋酸氟轻松植入剂对糖尿病视网膜病变进展与退变的长期影响

Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
PubMed 文献 · Ophthalmology · 2017-01-09

该研究为FAME A和B两项36个月前瞻性随机试验的事后分析,纳入糖尿病黄斑水肿患者,比较假对照与醋酸氟轻松(FAc)0.2或0.5微克/天对糖尿病视网膜病变(DR)进展至增殖性糖尿病视网膜病变(PDR)及DR严重程度量表(DRSS)变化的影响,发现FAc显著延迟PDR首次事件时间并改善DR严重程度。

要点

  • FAc治疗组首次PDR事件时间较假对照组显著延迟(P < 0.001)。
  • 两种FAc剂量在6、12、18个月时平均DR严重程度较假对照组有统计学显著改善。
  • 0.5微克/天FAc组达到3步及以上DR严重程度改善者与假对照组有统计学显著差异。

核心结论

  • 在糖尿病黄斑水肿受试者中,FAc持续眼内递送可延缓PDR的发生并减缓糖尿病视网膜病变的进展。

研究设计与样本

  • FAME A和B两项36个月前瞻性随机试验的事后分析。
  • 受试者为接受假对照或FAc 0.2或0.5微克/天的糖尿病黄斑水肿患者。
  • 由设盲阅读中心(威斯康星大学麦迪逊分校)采用标准7视野立体眼底照相和荧光素血管造影分别判定DRSS分级和视网膜灌注状态。

主要发现

  • 在整合的FAME数据集中,与假对照组相比,FAc治疗组首次PDR事件时间显著延迟(P < 0.001),该效应在基线DR更严重和慢性DME亚组中得到证实。
  • 基线存在视网膜非灌注的受试者接受FAc治疗后PDR进展减少更明显。
  • 两种FAc剂量在6、12、18个月时平均DR严重程度较假对照组有统计学显著改善。
  • 接受FAc的受试者中达到2步及以上或3步及以上DR严重程度改善的人数在数值上多于假对照组;相反,接受FAc的受试者中达到2步及以上或3步及以上DR严重程度恶化的人数更少。
  • 0.5微克/天FAc组达到3步及以上改善与假对照组有统计学显著差异。

关键数值与推荐

  • 主要结局为研究眼进展至PDR的复合临床结局,包括:(1)基于分级眼底照相从非增殖性糖尿病视网膜病变(NPDR)进展至PDR,(2)全视网膜光凝(PRP),或(3)因PDR行经平坦部玻璃体切除术(PPV);以及研究眼DRSS变化。
  • 采用对数秩检验进行3个治疗组间两两比较,未校正协变量,主要比较为假对照与0.2微克/天FAc。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effects of fluocinolone acetonide (FAc) on the progression to proliferative diabetic retinopathy (PDR) and the impact of FAc on changes in Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy (DR) severity scale (DRSS) grade during the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) A and B Phase III clinical trials. DESIGN: Post hoc analysis of data from the 36-month prospective, randomized, FAME A and B trials. PARTICIPANTS: Patients with diabetic macular edema (DME) who received sham control or FAc 0.2 or 0.5 μg/day. METHODS: A masked reading center (University of Wisconsin-Madison) determined DRSS grade and retinal perfusion status using standard 7-field stereo fundus photography and fluorescein angiography, respectively. Retinopathy changes over time were determined by DRSS step differences from baseline to month 36. Pairwise comparisons between the 3 treatment groups were performed using a log-rank test without adjustment for covariates, with the primary comparison between sham control and 0.2 μg/day FAc. MAIN OUTCOME MEASURES: Study eye progression to PDR based on a composite clinical outcome of (1) progression from nonproliferative diabetic retinopathy (NPDR) to PDR based on graded fundus photographs, (2) panretinal photocoagulation (PRP), or (3) pars plana vitrectomy (PPV) for PDR; and study eye changes on the DRSS. RESULTS: In the integrated FAME data set, compared with sham control-treated subjects, time to first PDR event was significantly delayed in subjects treated with FAc (P < 0.001), and this effect was confirmed in subgroups with more severe DR and chronic DME at baseline. In addition, subjects with retinal nonperfusion at baseline showed greater reduction in progression to PDR with FAc treatment. Both FAc dosages demonstrated statistically significant improvements in mean DR severity compared with sham treatment at months 6, 12, and 18. Numerically more subjects who received FAc experienced 2-or-more- or 3-or-more-step improvements in DR severity compared with subjects who received sham; conversely, fewer subjects treated with FAc experienced 2-or-more- or 3-or-more-step worsening in DR severity. The 3-or-more-step improvement with 0.5 μg/day FAc was statistically significantly different from sham control. CONCLUSIONS: In subjects with DME, sustained intraocular delivery of FAc slows development of PDR and slows progression of diabetic retinopathy.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Wykoff CC, Chakravarthy U, Campochiaro PA, et al. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy. Ophthalmology. 2017. PMID: 28081945. doi:10.1016/j.ophtha.2016.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。